Commercialising genetically engineered animal biomedical products
Eddie J. Sullivan A B , Jerry Pommer A and James M. Robl A
+ Author Affiliations
- Author Affiliations
A Hematech Inc., 4401 S. Technology Dr., Sioux Falls, SD 57106, USA.
B Corresponding author. Email: esullivan@hematech.com
Reproduction, Fertility and Development 20(1) 61-66 https://doi.org/10.1071/RD07182
Published: 12 December 2007
Abstract
Research over the past two decades has increased the quality and quantity of tools available to produce genetically engineered animals. The number of potentially viable biomedical products from genetically engineered animals is increasing. However, moving from cutting-edge research to development and commercialisation of a biomedical product that is useful and wanted by the public has significant challenges. Even early stage development of genetically engineered animal applications requires consideration of many steps, including quality assurance and quality control, risk management, gap analysis, founder animal establishment, cell banking, sourcing of animals and animal-derived material, animal facilities, product collection facilities and processing facilities. These steps are complicated and expensive. Biomedical applications of genetically engineered animals have had some recent successes and many applications are well into development. As researchers consider applications for their findings, having a realistic understanding of the steps involved in the development and commercialisation of a product, produced in genetically engineered animals, is useful in determining the risk of genetic modification to the animal v. the potential public benefit of the application.
Additional keywords: biopharmaceutical, cell banking, genetically modified, process development, quality systems, risk management, transgenic.
References
Auerswald, P. E. , and Branscomb, L. M. (2003). Valleys of death and Darwinian seas: financing the invention innovation transition in the United States. J. Technol. Transf. 28, 227–239.
| Crossref | GoogleScholarGoogle Scholar |
EMEA (2004). ‘Note for Guidance on Minimizing the Risk of Transmitting Animal Spongiform Encephalopathy Agents via Medicinal Products.’ Available at http://www.emea.europa.eu/pdfs/human/bwp/TSE%20NFG%20410-rev2.pdf [Verified 19 October 2007].
EMEA (2006a). ‘Summary of Product Characteristics, ATryn 1750 IU powder for solution for infusion.’ Available at http://www.emea.europa.eu/humandocs/PDFs/EPAR/atryn/H-587-PI-en.pdf [Verified 19 October 2007].
EMEA (2006b). ‘ATryn Scientific Discussions.’ Available at http://www.emea.europa.eu/humandocs/PDFs/EPAR/atryn/058706en6.pdf [Verified 19 October 2007].
FAO (2002). ‘Good Agricultural Practices.’ Available at http://www.fao.org/ag/magazine/GAP-V2-June02.pdf [Verified 19 October 2007].
Food and Drug Administration (1993). ‘Points to Consider in the Characterization of Cell Lines Used to Produce Biologicals.’ Available at http://www.fda.gov/cber/gdlns/ptccell.pdf [Verified 19 October 2007].
Food and Drug Administration (1995). ‘Points to Consider in the Manufacturing and Testing of Therapeutic Products for Human Use Derived From Transgenic Animals.’ Available at http://www.fda.gov/cber/gdlns/ptc_tga.txt [Verified 19 October 2007].
Food and Drug Administration (1997). ‘21 CFR. Animal Proteins Prohibited in Ruminant Feed, Part 589.2000.’ Available at http://www.fda.gov/cvm/Images/6597bse.pdf [Verified 19 October 2007].
Food and Drug Administration (2001). ‘Q7A Good Manufacturing Practices Guidance for Active Pharmaceutical Ingredients.’ Available at http://www.fda.gov/cder/guidance/4286fnl.htm [Verified 19 October 2007].
Food and Drug Administration (2006a). ‘Quality Systems Approach to Pharmaceutical CGMP Regulations.’ Available at http://www.fda.gov/cder/guidance/7260fnl.pdf [Verified 19 October 2007].
Food and Drug Administration (2006b). ‘Guidance for the Industry Q9 Quality Risk Management.’ Available at http://www.fda.gov/cder/guidance/7153fnl.htm [Verified 19 October 2007].
Food and Drug Administration (2006c). ‘21 CFR. Good Manufacturing Practices for Finished Pharmaceuticals. Part 211.165 Testing and Release for Distribution.’ Available at http://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfcfr/CFRSearch.cfm?fr=211.165 [Verified 19 October 2007].
Food and Drug Administration (2007). ‘Green Book.’ Available at http://www.fda.gov/cvm/green_book/aboutgbook.htm [Verified 19 October 2007].
Golovan, S. P. , Meidinger, R. G. , Ajakaiye, A. , Cottrill, M. , and Wiederkehr, M. Z. , et al. (2001). Pigs expressing salivary phytase produce low-phosphorus manure. Nat. Biotechnol. 19, 741–745.
| Crossref | GoogleScholarGoogle Scholar | PubMed |
IETS (1998). ‘Assay of Embryos and Ova Derived From Infected or Seropositive Dam. Manual of the International Embryo Transfer Society.’ (IETS: Savoy, IL.)
Keefer, C. L. , Pommer, J. , and Robl, J. M. (2007). The role of transgenic livestock in the treatment of human disease. CAST Issue Paper 35, 1–11.
National Institutes of Health (2002). ‘NIH Guidelines for Research Involving Recombinant DNA Molecules.’ Available at http://www4.od.nih.gov/oba/rac/guidelines_02/NIH_Gdlnes_lnk_2002z.pdf [Verified 19 October 2007].
National Research Council (1996). ‘Guide for the Care and Use of Laboratory Animals.’ (National Academy Press: Washington, D. C.)
OSTP-CEQ (2001). ‘CEQ and OSTP Assessment: Case Studies of Environmental Regulations for Biotechnology.’ Available at http://www.ostp.gov/html/ceq_ostp_study1.pdf [Verified 19 October 2007].
Pommer J., Nichols M., Kasinathan P., Sullivan E., Robl J., Griffin J., Boerema P., and Vos C. (2008). Viral risk assessment of harvest bovine oocytes from abattoir origin. In ‘Annual Meeting of the International Embryo Transfer Society’, Denver, Colorado. (In press.)
Prather, R. S. (2006). Cloned transgenic heart-healthy pork? Transgenic Res. 15, 405–407.
| Crossref | GoogleScholarGoogle Scholar | PubMed |
USDA-APHIS (1999). ‘9 CFR. Animals and Animal Products, Chapter I, Part 113.46–47, Viral Testing.’ Available at http://www.access.gpo.gov/nara/cfr/waisidx_99/9cfr113_99.html [Verified 19 October 2007].
USDA-APHIS FSIS (2007). ‘9 CFR. Animals and Animal Products, Chapter II, Part 309–310, Ante and Post-Mortem Inspections.’ Available at http://www.access.gpo.gov/nara/cfr/waisidx_07/9cfrv2_07.html [Verified 19 October 2007].
van Doorn, M. B. , Burggraaf, J. , van Dam, T. , Eerenberg, A. , Levi, M. , Hack, C. E. , Schoemaker, R. C. , Cohen, A. F. , and Nuijens, J. (2005). A phase I study of recombinant human C1 inhibitor in asymptomatic patients with hereditary angioedema. J. Allergy Clin. Immunol. 116, 876–883.
| Crossref | GoogleScholarGoogle Scholar | PubMed |
Wiebe, M. E. , and May, L. H. (1990). Cell banking. Bioprocess Technol. 10, 147–160.
| PubMed |
